Development Reports. In advance of each JSC meeting, unless otherwise agreed between the Parties, Janssen shall provide to the JSC a high-level summary report summarizing its Development activities with respect to each Licensed Product and the results thereof since the previous JSC meeting, and its anticipated Development activities with respect to each Licensed Product for the subsequent calendar quarter. At each JSC meeting, Janssen shall provide additional information as reasonably requested by Fate’s JSC representatives with respect to the Development activities summarized in such report or otherwise conducted or anticipated to be conducted for Licensed Products.

Development Reports. In advance of each meeting of the JDC, unless otherwise agreed between the Parties, Janssen will provide to the JDC a ​.

Development Reports. Abbott shall keep the JSC regularly informed of the progress of its efforts to Develop Compounds in the Field and in the Territory. Without limiting the generality of the foregoing, Abbott shall, at least once per Calendar Quarter, provide the JSC with reports in reasonable detail regarding the status of all pre-clinical IND-enabling studies and activities (including toxicology and pharmacokinetic studies), clinical trials and other activities conducted under each Development Plan, together with summary data and results and raw data made available if requested for each such pre-clinical IND-enabling study or activity, clinical trial and such additional information that it has in its possession as may be reasonably requested from time to time by the JSC.

Development Reports. No later than ​ following the end of each full Calendar Year during which Licensee is conducting Development activities hereunder, Licensee shall provide [[AstraZeneca:Organization]] with a written report for review and discussion of such Development activities it has performed, or caused to be performed, since the preceding report (or, with respect to the first such report, since the Effective Date), its Development activities in process and the future activities it expects to initiate during the following twelve (12)-month period. Each such report shall be ​ of Licensee’s Development activities as compared to the Product Development Plan, including: # ​ and # ​. Notwithstanding the foregoing, if [[AstraZeneca:Organization]] markets or has in development a competing pharmaceutical product or product candidate ​, Licensee, acting reasonably, shall be entitled to omit those certain details it

Development Reports. [[3D Medicines:Organization]] shall keep [[Aravive:Organization]] reasonably informed as to the progress and results of [[3D Medicines:Organization]]’, its Affiliates’ and their respective Sublicensees’ Development activities (including prompt reporting of available clinical Data). Without limiting the foregoing, at each regularly scheduled JSC meeting, [[3D Medicines:Organization]] shall provide [[Aravive:Organization]] with a reasonably detailed written report summarizing its Development activities performed since the last JSC meeting and the results thereof, as reasonably sufficient to enable [[Aravive:Organization]] to determine [[3D Medicines:Organization]]’ compliance with its diligence obligations under Section 4.1. At such JSC meeting, the Parties shall discuss the status, progress and results of [[3D Medicines:Organization]]’, its Affiliates’ and their respective Sublicensees’ Development activities. [[3D Medicines:Organization]] shall promptly respond to [[Aravive:Organization]]’s reasonable questions or requests for additional information relating to such Development activities. In addition, within thirty (30) days after the end of each Fiscal Year, [[3D Medicines:Organization]] shall provide [[Aravive:Organization]] with a detailed written annual report regarding the progress of its Development activities and any results therefrom.

Development Reports. Acadia shall keep Stoke, via the JDC, reasonably informed as to the progress and results of its and its Affiliates’ and Sublicensees’ Development activities under this Agreement for each Development Program (“Development Records”). Without limiting the foregoing, Acadia shall provide Stoke with regular reports (but in any event no less than every ​) summarizing its Development of Licensed Products under each Development Program and the results of such Development. Such reports shall be at a level of detail sufficient to enable Stoke to determine Acadia’s compliance with its diligence obligations under [Section 5.2(c)]. Without limiting the foregoing, Acadia may respond to Stoke’s reasonable questions or requests for additional information relating to such Development activities for each Development Program.

Development Reports. Ji Xing shall keep [[Cytokinetics:Organization]] reasonably informed as to the progress and results of its and its Affiliates’ and sublicensees’ Development of the Product. Without limiting the foregoing, the status, progress and results of the Development of the Product in the Territory shall be discussed at meetings of the JDC. At least ​ before each regularly scheduled JDC meeting, Ji Xing shall provide the JDC with a written report summarizing its Development activities and the results thereof, covering subject matter at a level of detail reasonably required by [[Cytokinetics:Organization]] and sufficient to enable [[Cytokinetics:Organization]] to determine Ji Xing’s compliance with its diligence obligations pursuant to Section 4.2. In addition, Ji Xing shall make available to [[Cytokinetics:Organization]] such additional information about its Development activities as may be reasonably requested by [[Cytokinetics:Organization]] from time to time.

Development Reports. Until the First Commercial Sale of a Product, Coya will provide to ARScience Bio, within 60 days after the end of each Calendar Year, a written report summarizing Coya’s and its Affiliates’ and Sublicensees’ activities to Develop the Licensed Compound and Products, including # a high-level summary of the data and results of such Development efforts and # identification of # the Regulatory Approval Applications that Coya or its Affiliates or Sublicensees have filed, sought or obtained in the prior 12-month period and # any such filings they reasonably expect to make, seek or attempt to obtain in the following 12-month period. Within 30 days after receipt of each report under this Section 3.1.3 (Development Reports), ARScience Bio may request a meeting (including by teleconference or videoconference) with representatives of Coya to discuss the report and the status of Development of Products, the location and date of such meeting to be mutually agreed upon by the Parties.

Development Reports. Licensee will provide MSD with reasonably detailed written reports describing its progress with respect to its Development efforts (each, a “Development Report”). Such Development Reports will be furnished on ​.

Development Reports. At each JSC meeting for ​ during which either Party is performing, or having performed, Development activities for any Option Compound, Option Product, Licensed Compound or Licensed Product in the Territory, such Party will provide a report to the other Party (through the JSC) summarizing such Development activities performed during the period since the preceding JSC meeting, such Development activities as are in process, including a summary of the data and results of such Development activities.